Chemical Identity
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino acid peptide engineered as a dual incretin receptor agonist — the first of its class to be studied for simultaneous agonism of both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). The molecule incorporates a C20 fatty diacid moiety via a gamma-glutamic acid linker, a structural modification that enables extended plasma half-life through albumin binding. The peptide sequence is derived from the native GIP hormone with additional modifications to achieve balanced GLP-1R and GIPR activity profiles.
- Peptide class: Synthetic acylated peptide; GLP-1/GIP dual receptor agonist (twincretin)
- Structure: 39 amino acids; C20 fatty diacid via gamma-glutamic acid/mini-PEG linker; Aib substitutions at positions 2 and 13 for protease resistance
- Half-life mechanism: Albumin binding via fatty diacid chain; studied for extended duration in receptor binding kinetics research
- Origin: Developed by Eli Lilly and Company; first described in peer-reviewed literature beginning in the mid-2010s; FDA-approved as Mounjaro (2022) and Zepbound (2023) as pharmaceutical drug products
- Research grade distinction: Sequence Labs tirzepatide is a research compound distinct from and not equivalent to Mounjaro or Zepbound — supplied exclusively for laboratory and preclinical research purposes
Important: Sequence Labs tirzepatide is a research-grade compound intended for in vitro and preclinical laboratory research by licensed researchers only. It is not an FDA-approved pharmaceutical product and is not equivalent to, nor a substitute for, Mounjaro® or Zepbound® (Eli Lilly). For research use only. Not for human use.
Published Research
Research Background
Peer-reviewed literature on tirzepatide has examined a range of receptor pharmacology and incretin biology questions. Published research consistently frames tirzepatide as a mechanistically distinct compound compared to selective GLP-1 mono-agonists, owing to its engagement of the GIPR alongside GLP-1R. The following areas represent the primary domains investigated in published research.
Explore the full body of published research: Search tirzepatide on PubMed →
Available Vial Sizes & Pricing
Sequence Labs Tirzepatide Supply
Research-grade tirzepatide available in six vial sizes for preclinical, in vitro, and laboratory research applications. All vials lyophilized, batch-tested, and shipped with COA documentation.
| Vial Size | Research Price | Purity | COA |
|---|---|---|---|
| 5mg | $48.99 | ≥98–99% HPLC + MS | ✓ Krause Analytical |
| 10mg | $70.99 | ≥98–99% HPLC + MS | ✓ Krause Analytical |
| 15mg | $97.99 | ≥98–99% HPLC + MS | ✓ Krause Analytical |
| 20mg | $128.99 | ≥98–99% HPLC + MS | ✓ Krause Analytical |
| 30mg | $148.99 | ≥98–99% HPLC + MS | ✓ Krause Analytical |
| 40mg | $234.99 | ≥98–99% HPLC + MS | ✓ Krause Analytical |
- Independent testing: Every batch tested by Krause Analytical (Austin, TX) for identity, purity, and potency via HPLC and mass spectrometry
- COA transparency: Batch-specific certificates of analysis are publicly accessible and cross-verifiable through Finnrick Pulse
- Sabrina Runbeck, PA-C: The Sequence Labs catalog is reviewed by a licensed Physician Assistant-Certified (PA-C) for compound integrity and catalog accuracy
- Lyophilized format: All vials shipped as lyophilized powder for stability during storage and transit; supplied with research data sheet
- Wholesale available: Tiered B2B pricing for licensed practitioners, compounders, and research institutions — inquire via the wholesale portal
Laboratory Reference
Reconstitution Reference
The following is a general laboratory reference for researchers preparing research-grade lyophilized tirzepatide for in vitro or preclinical study. This information is for qualified researchers only and is not a protocol for human use.
Research use only. Reconstitution guidance is provided for laboratory reference purposes. Tirzepatide research preparations are intended exclusively for preclinical and in vitro research by licensed researchers. Not for human use, self-experimentation, or clinical application.
- 1 Allow vial to equilibrate. Remove the research sample from cold storage and allow the sealed lyophilized vial to reach room temperature (approximately 15–20 minutes) before introducing solvent. This reduces condensation and improves consistent solvent introduction.
- 2 Prepare sterile solvent. Bacteriostatic water (0.9% benzyl alcohol) is the standard solvent for tirzepatide research preparations. Sterile saline is an alternative for short-term use. Prepare the required volume based on target research concentration.
- 3 Introduce solvent slowly. Direct solvent toward the inner glass wall rather than directly onto the lyophilized cake. Introduce solvent incrementally to avoid excessive foaming or mechanical disruption of the peptide structure.
- 4 Gently swirl — do not agitate. Gently rotate the vial between fingers until the lyophilized material has dissolved completely. Do not vortex or shake vigorously, as this may introduce air bubbles or cause peptide aggregation.
- 5 Inspect and label. Inspect the reconstituted research preparation for visible particulate matter or cloudiness before use. Label with compound name, concentration, preparation date, and batch number from the COA. Store per the data sheet conditions.
- 6 Storage of reconstituted preparation. Reconstituted tirzepatide research preparations should be stored refrigerated (2–8°C) and used within the window specified on the accompanying research data sheet. Do not refreeze reconstituted preparations unless validated in the research protocol.
Common Questions